Traumatic Brain Injury (TBI)
Psychedelics are being investigated for their potential therapeutic effects on Traumatic Brain Injury (TBI), a condition that frequently results in various physical and psychological impairments. Early preclinical studies suggest that these compounds may influence inflammatory responses, promote neuroplasticity, and enhance neurogenesis, offering new avenues for treatment.
Key Insights
- 1
Mental health disorders are prevalent post-TBI, often exacerbating recovery challenges.
- 2
Early evidence suggests psychedelics can have physiological benefits, targeting inflammation and promoting brain repair mechanisms.
- 3
Research involving psychedelics remains primarily in preclinical phases, highlighting an area ripe for exploration.
What is Traumatic Brain Injury (TBI)?
Traumatic brain injury (TBI) occurs when an external force causes damage to the brain, leading to alterations in brain function. This can result from falls, sports injuries, or accidents, and TBI is characterised by a wide range of physical and psychological symptoms that can vary in severity.
TBI is classified into mild, moderate, and severe categories. Mild TBI, or concussion, is the most common form and accounts for the majority of cases. Symptoms can include headache, confusion, and mood disorders, while moderate to severe injuries often present with more pronounced cognitive deficits and physical complications.
Diagnosing TBI can be complex and is typically reliant on clinical assessments and neuroimaging techniques. Treatment approaches vary based on the severity of injury, with an emphasis on preventing secondary brain damage and facilitating rehabilitation.
Current Treatments
Treatment for TBI ranges from rest and over-the-counter pain relief in mild cases to emergency medical interventions and rehabilitation for moderate to severe TBI. There are currently no FDA-approved medications specifically for TBI; hence standard care focuses on symptom management and recovery support.
Psychedelic Effect Matrix
Compound efficacy and evidence levels for Traumatic Brain Injury (TBI).
| Compound | Magnitude | Evidence | Consistency |
|---|---|---|---|
| Psilocybin Supported by animal studies demonstrating effects on neurogenesis and recovery post-TBI. | Medium | Moderate | Consistent |
| LSD Demonstrated potential in enhancing neuroplasticity, supported by preclinical research. | Medium | Moderate | Consistent |
| DMT Shows promise in modulating inflammation, as evidenced in animal model studies. | Medium | Moderate | Consistent |
| MDMA Has shown benefits in treating associated mental health disorders, relevant post-TBI. | Medium | Moderate | Moderate |
Psilocybin and Traumatic Brain Injury (TBI)
Psilocybin acts primarily through serotonin receptors and has been shown to promote neurogenesis and synaptic connectivity in the brain. Its ability to enhance neuroplasticity suggests that it may facilitate recovery from brain injuries by supporting the brain's structural repair and functional recovery mechanisms following TBI.
LSD and Traumatic Brain Injury (TBI)
LSD is noted for its potential to promote brain plasticity by increasing dendritic spine density. This action may foster the brain's capacity to adapt following injury, potentially improving cognitive outcomes in patients with TBI through enhanced synaptic resilience.
DMT and Traumatic Brain Injury (TBI)
DMT's interaction with serotonin receptors, particularly the sigma-1 receptors, is believed to help mitigate inflammation in the brain, a common consequence of TBI. By reducing inflammatory responses and promoting protective brain signalling, DMT may aid in the recovery process after injury.
MDMA and Traumatic Brain Injury (TBI)
MDMA has been documented to influence mood and emotional resilience, which is critical for individuals recovering from TBI. Additionally, its potential to support neuroplasticity may provide benefits in cognitive and emotional rehabilitation.
Clinical Outlook
As research progresses, the potential of psychedelics in treating TBI may lead to innovative therapies that address both the neurological and psychological repercussions of these injuries. A concerted effort is needed to transition findings from preclinical studies into clinical applications that could revolutionise TBI treatment.
Industrial Landscape
Key players in this space include Lobe Sciences, Wesana Health, Revive Therapeutics, and organisations engaged in the development of psychedelic treatments specifically aimed at addressing TBI-related symptoms and recovery through innovative protocols.
Quick Indicators
Related Topics
Organisations
Search →University of Amsterdam
The University of Amsterdam (UvA) is one of the Netherlands' leading research universities, with its Amsterdam UMC Department of Psychiatry conducting clinical trials on psilocybin and psychedelic-assisted therapies for treatment-resistant mental health conditions.
Columbia University
Research with psychedelics has been taking place at Columbia University in New York since 2014. Researchers from various departments at the university including Medicine, Psychology and Psychiatry have conducted numerous trials investigating the effects ketamine has on substance use disorders. Some research exploring the anti-depressant effects of ketamine has also taken place. More recently, Columbia University served as a test site for COMPASS Pathway's COMP360 trial which explored the effects of psilocybin on treatment-resistant depression. Professor of Clinical Psychiatry, Dr David Hellerstein served as the principal investigator at this study site.
Johns Hopkins University
The Centre for Psychedelic and Consciousness Research focuses on how psychedelics affect behavior, cognition, brain function, and biological health markers. They have been at the forefront of demonstrating the safety and efficacy of psychedelics for mental disorders, expanding their focus into psilocybin research across multiple mental health conditions, including smoking cessation, major depressive disorder, and cancer-related anxiety.
Stanford University
At the Stanford School of Medicine, researchers from the Rodriguez Lab and the Heifets Lab have united under the banner of the Stanford Psychedelic Science Group. Their primary clinical focus is to investigate compounds including ketamine, psilocybin, and MDMA as potential treatments for debilitating disorders such as obsessive-compulsive disorder (OCD), treatment-resistant depression, and post-traumatic stress disorder (PTSD).
AZ Delta
AZ Delta is a major Belgian hospital group headquartered in Roeselare, Flanders, operating four campuses with 1,403 approved beds. It participates in the multi-centre BIKe (Brain Injury and Ketamine) randomized controlled trial (NCT05097261) investigating ketamine's safety as an adjunct sedative in severe traumatic brain injury.
AZ Sint-Jan AV
AZ Sint-Jan Brugge-Oostende AV is a leading Belgian teaching hospital in Bruges with a dedicated Clinical Trial Center (CTC) that sponsors and participates in academic and commercial drug studies. Its Department of Anesthesiology and Intensive Care Medicine is a confirmed site in the BIKe (Brain Injury and Ketamine) randomized controlled trial (NCT05097261) investigating ketamine's role in severe traumatic brain injury management.
AZ Turnhout
AZ Turnhout is a general hospital in Turnhout, Antwerp province, Belgium, providing comprehensive medical and surgical care to the northern Campine region. Its Department of Anesthesiology and Intensive Care Medicine is a confirmed site in the BIKe (Brain Injury and Ketamine) randomized controlled trial (NCT05097261) investigating ketamine as an adjunct sedative in severe traumatic brain injury patients.
Brooke Army Medical Center
Brooke Army Medical Center (BAMC) at Joint Base San Antonio is the US Army's flagship medical institution and the Department of Defense's only Level I Trauma Center, and has been a primary site in multi-center randomized controlled trials investigating ketamine for antidepressant-resistant PTSD in active duty military and veterans. BAMC researchers have also contributed to pilot studies on service members' perspectives on psychedelic-assisted therapies including MDMA and psilocybin for PTSD and traumatic brain injury.
Centre Hospitalier Régional de la Citadelle
CHR de la Citadelle is a large public hospital in Liège, Belgium, whose Department of Anesthesia and Intensive Care participated in the first double-blind placebo-controlled feasibility trial of sub-anesthetic ketamine for prolonged disorders of consciousness, demonstrating increased brain complexity and reduced spastic paresis.
Copenhagen Trial Unit, Center for Clinical Intervention Research
The Copenhagen Trial Unit (CTU), Centre for Clinical Intervention Research, is a non-specialty clinical research unit at Rigshospitalet (Copenhagen University Hospital), supporting rigorous randomised clinical trials and systematic reviews across all medical disciplines since 2000. Located at the same hospital campus as the Neurobiology Research Unit conducting active psilocybin neuroimaging studies, CTU provides the trial methodology, statistical expertise, and conduct infrastructure that enables clinical psychedelic research in Denmark.
Henry M. Jackson Foundation for the Advancement of Military Medicine
The Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF) is a congressionally chartered non-profit founded in 1983 that manages research contracts and grants for the U.S. Department of Defense across global health, HIV, TBI, and PTSD. HJF is affiliated with clinical research investigating ketamine for sedation in severe traumatic brain injury — a condition at the intersection of military medicine and emerging ketamine-based therapies.
Imelda Hospital, Bonheiden
Imelda Hospital is a Catholic general hospital in Bonheiden, in the Antwerp province of Belgium, offering a full range of acute care and specialist services across approximately 550 beds. The hospital has contributed to clinical research on ketamine for the management of acute brain injury patients.
People
Search →Jessica Maples-Keller
Associate Professor in the Emory School of Medicine, Department of Psychiatry and Behavioral Sciences; Associate Director of the Emory Healthcare Veterans Program
She is a prominent translational PTSD and psychedelic-therapy researcher contributing to MDMA and psilocybin studies, including work on fear extinction, treatment barriers, and culturally informed psychedelic-assisted therapy.
Alan Davis
Associate Professor of Social Work & Director, Center for Psychedelic Drug Research
Noted for advancing epidemiological, naturalistic and mixed-method research on therapeutic and adverse outcomes of psychedelics and for translating those findings into clinical and harm-reduction contexts.
Nathan Sepeda
Director of Data & Analytics
Notable for his contributions to clinical and experimental studies of psilocybin-assisted interventions, including trials of major depressive disorder and investigations of enduring psychological and neurofunctional effects.
Robin Carhart-Harris
Ralph Metzner Distinguished Professor
Pioneering researcher in brain imaging of psychedelics and founding director of the UCSF Neuroscape Psychedelics Division.
David Erritzoe
Clinical Associate Professor in Psychopharmacology
Head of the Centre for Psychedelic Research at Imperial College London and director of the CIPPRes Clinic.
Leor Roseman
Senior Lecturer and Psychedelic Researcher
Expert in the psychological and social impacts of psychedelics and their potential in conflict resolution.
Hannes Kettner
Research Specialist at UCSF and PhD Candidate at Imperial College London
A leading expert in the observational study of 'set and setting' and its influence on the psychedelic experience.
Matthew Johnson
Professor of Psychiatry
A leading clinical researcher who has advanced evidence on the therapeutic potential and safety of classic psychedelics—particularly psilocybin—for addiction and mental health outcomes through clinical trials, survey research and methodological guidance.
Lauren Averill
Researcher
Noted for clinical and translational research on psychedelic-assisted treatments for trauma-related disorders, particularly among military and veteran populations, and for contributions to ethical and implementation issues in psychedelic medicine.
Simon Ruffell
Psychiatrist and psychedelic researcher; Senior Research Associate at King's College London / affiliated with Onaya Science
He is notable for leading and coauthoring naturalistic and review studies on ayahuasca and psilocybin, including work on veterans, mental health outcomes, EEG, epigenetics, and the gut-brain axis.
Yitong Xin
Assistant Professor at the College of Social Work, University of Utah
Xin is notable for psychedelic and psychiatric research on trauma, substance use, and cultural/racial outcomes, including work on special operations veterans and people of color.
Martin Polanco
M.D.; Founder of The Mission Within and Clinic Founder/Psychedelic Researcher
He is notable for clinical and phenomenological research on ibogaine and 5-MeO-DMT, especially in addiction and veteran mental health contexts.
Connected Evidence
The latest clinical data and verified academic findings associated with Traumatic Brain Injury (TBI).